Rose Pharma-Sponsored Patient Preference Research Accepted for Presentation at ObesityWeek® 2026
PRESS RELEASE
- Research examines patient preferences for flexibility and control in obesity treatment
VIRGINIA BEACH, Va. — September 9, 2026. Rose Pharma Inc. is pleased to announce that its sponsored abstract, led by Angela Fitch, MD, FACP, MFOMA, Dipl. ABOM, entitled “Why Adults With Obesity Decline GLP-1 Therapy: Preference for Limited Medication Exposure,” has been accepted for poster presentation at ObesityWeek® 2026, The Obesity Society’s 44th Annual Meeting, taking place November 14–17, 2026 in Washington, DC.
The accepted research is based on an IRB-approved patient-preference study of adults who had been recommended weight-management therapy.
The study examines patient preferences regarding potential GLP-1 treatment characteristics, including flexibility, patient control over when medication is used, treatment duration, and other attributes that may influence treatment interest and adoption.
The research was designed to provide greater insight into how people considering obesity treatment evaluate different treatment profiles and to help inform the continued evolution of patient-centered obesity care.
Consistent with The Obesity Society’s embargo policy, detailed study findings and conclusions will not be disclosed prior to the official ObesityWeek® embargo lift.
ObesityWeek® 2026 Poster Presentation
The poster will be presented in person during ObesityWeek® 2026. Poster sessions are scheduled for:
- Saturday, November 14: 7:30–8:30 PM
- Sunday, November 15: 2:30–3:30 PM
- Monday, November 16: 2:30–3:30 PM
The specific Rose Pharma presentation date and additional poster details will be announced once confirmed.
Rose Pharma is pleased to contribute to the scientific dialogue at ObesityWeek® and to support research focused on better understanding the perspectives and treatment preferences of people living with obesity.
About Rose Pharma Inc.
Rose Pharma Inc. is a clinical-stage biopharmaceutical company developing ROSE-010, a rapid-acting, short-duration GLP-1 receptor agonist for weight management and acute pain associated with irritable bowel syndrome (IBS). Rose Pharma is focused on developing differentiated treatment approaches designed to address important unmet patient needs.